SDC2 and diabetic cardiomyopathy: With CD362+-selected MSCs being a homogeneous cell product that meets regulatory requirements for clinical use, the present study aimed to gain further insights into the impact of CD362+-selected MSC application on the pathogenesis of experimental diabetic cardiomyopathy, especially on the mechanisms underlying diastolic dysfunction.